UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
October
24, 2014
Commission
File #: 000-53723
TAURIGA
SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Florida
(State
or other jurisdiction of incorporation)
30-0791746
(IRS
Employer Identification Number)
39
Old Ridgebury Road
Danbury,
Connecticut 06180
(Address
of principal US executive offices)
Tel:
(858) 353-5749
(Registrant’s
telephone number)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions:
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
ITEM
5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On
October 24, 2014, Michael J. Brennan, M.D., Ph.D. was appointed as a member of the Board of Directors (the “Board”)
of Tauriga Sciences, Inc. (the “Company”). On October 27, 2014, Dr. Brennan was also appointed to serve as member
of the Compensation Committee of the Board.
Dr.
Brennan currently serves as the Managing Director of Pearl Street Venture Funds, a venture capital firm, a position he has held
since 2006. From December 2003 until December 2005, Dr. Brennan was a Managing Director of Coastview Capital, a venture capital
firm focused exclusively on life science investments. From September 2000 until April 2003, Dr. Brennan was a General Partner
of Oxford Biosciences Partners, a venture capital firm specializing in the financing of early stage healthcare companies. From
1996 until 2000, Dr. Brennan served as the Chief Executive Officer and member of the Board of Directors of Gene Logic Inc., a
publicly traded company. Dr. Brennan received a Ph.D. in neurobiology and an M.D. from the University of Witwatersrand, Johannesburg,
South Africa.
Family
Relationships
There are
no family relationships between any of the Company’s directors or officers and Dr. Brennan.
Related
Party Transactions
There
are no related party transactions with respect to Dr. Brennan reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation
S-K.
Compensatory
Arrangements
On
October 24, 2014, Dr. Brennan was granted 1,000,000 shares of the Company’s common stock, par value $0.001. All such shares
are “restricted securities” as such term is defined by the Securities Act of 1933, as amended. The Company has not
entered into any other compensatory agreements or plan with Dr. Brennan.
ITEM
9.01 Financial Statements and Exhibits
Exhibit
No. |
|
Description
of Exhibit |
|
|
|
99.1* |
|
Press
release issued on October 30, 2014 |
*filed herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
TAURIGA
SCIENCES, INC. |
|
|
|
Date:
October 30, 2014 |
By:
|
/s/ Stella
M. Sung |
|
|
Stella
M. Sung |
|
|
Chief
Executive Officer |
Tauriga
Sciences Inc. Appoints Michael J. Brennan, M.D., Ph.D. to its Board of Directors
Los
Angeles, CA — (October 30, 2014) Tauriga Sciences, Inc. (OTCQB: TAUG) or (“Tauriga” or “the Company”),
a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology
platform technology, announced the appointment of Michael J. Brennan, M.D., Ph.D. to its Board of Directors. Dr. Michael Brennan
was previously President and Chief Executive Officer of Gene Logic, a NASDAQ-listed company. During Dr. Brennan’s time at
Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion.
Dr. Brennan has previous experience in the biopharmaceutical industry, where he has served as Vice President, Business Development
for Boehringer Mannheim Therapeutics. Dr. Brennan brings operating experience, technical and industry knowledge, and a thorough
understanding of the NASDAQ market to the Tauriga Board of Directors.
Tauriga’s
Chairman and CEO Dr. Stella M. Sung stated, “Dr. Michael Brennan is an important addition to our Board of Directors at this
time, as we begin to generate revenues from our natural wellness business and grow our company to its next stage of evolution.
Dr. Brennan built a raw startup into a leading genomics company during the genomics revolution. His skills and firsthand experience
in building companies to seize new market opportunities are directly transferrable to the emerging medical marijuana and natural
wellness sector as well as to the “wastewater to value” industry.”
Dr.
Michael Brennan commented, “It is an honor to work with an emerging life sciences company such as Tauriga Sciences. As a
trained neurologist, I believe in the scientific and clinical rationale for Tauriga’s natural wellness line, which includes
topical cannabis creams as well as natural, amino acid-based dietary supplements. I am excited about establishing and growing
the customer base for Tauriga’s consumer product line. I am also enthusiastic about commercializing Tauriga’s synthetic
biology platform for remediating wastewater and generating energy in the process. Tauriga has great prospects, and it will be
truly rewarding to help Dr. Sung and her highly talented management team take the company to the next stage by focusing on strong
fundamentals and on rapid revenue growth.”
Dr.
Brennan will have an immediate impact on the Tauriga’s natural wellness business, which has recently launched and has begun
to generate revenues. Tauriga’s “Cannabis Complements” is a line of non-cannabis containing dietary supplements.
These dietary supplements target cannabis-related effects, such as anxiety, memory and cognitive function, and appetite control.
These supplements do not contain cannabis and can be sold nationwide to further build the Tauriga brand, especially in the 23
states where medicinal marijuana is legal. Among the current products are: “Satietiva,” a natural appetite suppressant;
“IndiCalm,” a natural relaxant and anxioytic; and “ClearNaze,” a natural, non-stimulant, non-drowsy decongestant.
In
addition to his leadership position at GeneLogic, Dr. Brennan has served as a General Partner or Managing Director of several
life science venture funds. Dr. Brennan received a B.S. in Biochemistry, a Ph.D. in neurobiology and a M.D. from the University
of Witwatersrand, Johannesburg, South Africa. He has seventy six publications in medical and scientific journals and textbooks.
About
Tauriga Sciences, Inc.:
Tauriga
Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness
sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build
a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders.
The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive
basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate,
and long terms. Please visit the Company’s corporate website at www.tauriga.com.
NON
SOLICITATION:
This
press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there
be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and
will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking
Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans
and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present
circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur
with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and
uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by
such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop
and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG
has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation
to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on
these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by
TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the
solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”)
or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption
from registration, under the Securities Act and applicable state securities laws.
Contact:
Tauriga
Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697
Email: ssung@tauriga.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024